JP2012176978A5 - - Google Patents

Download PDF

Info

Publication number
JP2012176978A5
JP2012176978A5 JP2012128849A JP2012128849A JP2012176978A5 JP 2012176978 A5 JP2012176978 A5 JP 2012176978A5 JP 2012128849 A JP2012128849 A JP 2012128849A JP 2012128849 A JP2012128849 A JP 2012128849A JP 2012176978 A5 JP2012176978 A5 JP 2012176978A5
Authority
JP
Japan
Prior art keywords
peptide
seq
pharmaceutical composition
carrier
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012128849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012176978A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012176978A publication Critical patent/JP2012176978A/ja
Publication of JP2012176978A5 publication Critical patent/JP2012176978A5/ja
Pending legal-status Critical Current

Links

JP2012128849A 2002-04-22 2012-06-06 プロテインキナーゼｃのペプチドインヒビター Pending JP2012176978A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37453002P 2002-04-22 2002-04-22
US60/374,530 2002-04-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003586176A Division JP2005523326A (ja) 2002-04-22 2003-04-22 プロテインキナーゼｃのペプチドインヒビター

Publications (2)

Publication Number Publication Date
JP2012176978A JP2012176978A (ja) 2012-09-13
JP2012176978A5 true JP2012176978A5 (enExample) 2013-04-18

Family

ID=29251202

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2003586177A Pending JP2005527209A (ja) 2002-04-22 2003-04-22 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター
JP2003586176A Withdrawn JP2005523326A (ja) 2002-04-22 2003-04-22 プロテインキナーゼｃのペプチドインヒビター
JP2009010402A Pending JP2009091372A (ja) 2002-04-22 2009-01-20 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター
JP2009011456A Pending JP2009102392A (ja) 2002-04-22 2009-01-21 プロテインキナーゼｃのペプチドインヒビター
JP2012128849A Pending JP2012176978A (ja) 2002-04-22 2012-06-06 プロテインキナーゼｃのペプチドインヒビター

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2003586177A Pending JP2005527209A (ja) 2002-04-22 2003-04-22 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター
JP2003586176A Withdrawn JP2005523326A (ja) 2002-04-22 2003-04-22 プロテインキナーゼｃのペプチドインヒビター
JP2009010402A Pending JP2009091372A (ja) 2002-04-22 2009-01-20 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター
JP2009011456A Pending JP2009102392A (ja) 2002-04-22 2009-01-21 プロテインキナーゼｃのペプチドインヒビター

Country Status (6)

Country Link
US (8) US7507711B2 (enExample)
EP (3) EP2332559A1 (enExample)
JP (5) JP2005527209A (enExample)
AU (4) AU2003234186B2 (enExample)
CA (3) CA2481512C (enExample)
WO (2) WO2003089456A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089456A2 (en) * 2002-04-22 2003-10-30 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
AU2003241559A1 (en) * 2003-05-16 2004-12-13 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase c peptides for use in withdrawal
WO2005032575A1 (en) * 2003-10-02 2005-04-14 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase c peptides for use in withdrawal
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) * 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
CA2549052A1 (en) * 2003-12-11 2005-06-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific antagonists of protein kinase c
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
US20060148700A1 (en) * 2004-11-10 2006-07-06 Daria Mochly-Rosen Methods and compositions for reducing injury to a transplanted organ
US20060160062A1 (en) * 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
WO2006108270A1 (en) * 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
US20100041597A1 (en) * 2005-08-05 2010-02-18 Jenny Phipps Peptides targeted to protein kinase c isoforms and uses thereof
CA2620364A1 (en) 2005-08-26 2007-03-01 David C. Yeomans Methods for treatment of headaches by administration of oxytocin
JP5269596B2 (ja) * 2005-09-19 2013-08-21 カイ ファーマシューティカルズ インコーポレーティッド 血管新生のプロテインキナーゼｃペプチドモジュレーター
JP2009531335A (ja) * 2006-03-30 2009-09-03 サルペップ バイオテクノロジー インコーポレイテッド 神経障害性疼痛の抑制および治療
WO2007143119A2 (en) * 2006-06-01 2007-12-13 The Board Of Trustees Of The Leland Stanford Junior University Method of preventing progression of hypertension-induced heart failure with pkc peptides
WO2008089491A2 (en) * 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
CN101678063B (zh) * 2007-01-19 2012-12-19 凯制药公司 使用ε抑制剂化合物减轻疼痛的方法
US20090062208A1 (en) * 2007-02-06 2009-03-05 Mochly-Rosen Daria D Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor
US20090062178A1 (en) * 2007-04-06 2009-03-05 Harrison Stephen D Methods of use of gamma inhibitor compounds for the attenuation of pain
WO2008154004A2 (en) * 2007-06-07 2008-12-18 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of tumor metastases using protein kinase c (pkc) inhibitors
WO2009085270A2 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of inhibitors of c0nnexin43 for treatment of fibrotic conditions
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
MX2010010569A (es) * 2008-03-27 2010-11-04 Nestec Sa Metodos para incrementar la absorcion de peptidos, peptidomimeticos y otros sustratos de proteina de transporte gastrointestinal.
WO2010019965A1 (en) * 2008-08-15 2010-02-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection
JP6189581B2 (ja) 2009-02-20 2017-08-30 セルラー ダイナミクス インターナショナル， インコーポレイテッド 幹細胞の分化のための方法および組成物
US8372642B2 (en) * 2009-02-27 2013-02-12 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
CA2754482A1 (en) * 2009-03-06 2010-09-10 Angstrom Pharmaceuticals, Inc. Compositions and methods for modulation of cell migration
WO2010111533A2 (en) * 2009-03-25 2010-09-30 Kai Pharmaceuticals, Inc. Transdermal delivery of pkc modulatory peptides through microporated skin
EP2942060A1 (en) 2009-09-29 2015-11-11 Joslin Diabetes Center, Inc. Use of Protein Kinase C Delta (PKCD) Inhibitors to Treat Diabetes, Obesity and, Hepatic Steatosis
AU2011223563A1 (en) * 2010-03-05 2012-11-01 Angstrom Pharmaceuticals, Inc. Modulation of intracellular signaling
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
JP6061932B2 (ja) 2011-08-12 2017-01-18 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ピルビン酸デヒドロゲナーゼキナーゼを特異的にレギュレートするための組成物および方法
EP2841563B1 (en) 2012-04-24 2019-06-12 Dan S. Kaufman Method for developing natural killer cells from stem cells
CA2923765C (en) 2013-09-18 2021-06-29 University Of Canberra Stem cell modulation ii
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors
AU2015309686B2 (en) 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
HRP20231438T1 (hr) 2015-01-07 2024-06-07 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i načini uporabe
MX2018012351A (es) 2016-04-12 2019-02-07 Trigemina Inc Formulaciones de oxitocina que contienen magnesio y metodos de uso.
US12410143B2 (en) 2017-01-17 2025-09-09 Michael David FORREST Therapeutic inhibitors of the reverse mode of ATP synthase
BR112019028172A2 (pt) 2017-07-13 2020-10-06 Michael David Forrest moduladores terapêuticos do modo reverso da atp sintase
JP2021502405A (ja) 2017-11-08 2021-01-28 エピアクシス セラピューティクス プロプライエタリー リミテッド 免疫原性組成物及びその使用
EP4078221A1 (en) * 2019-12-16 2022-10-26 Sony Semiconductor Solutions Corporation Time-of-flight imaging circuitry, time-of-flight imaging system, time-of-flight imaging method
US20230104831A1 (en) * 2020-03-31 2023-04-06 Toray Industries, Inc. An image analysis device, a control method for an image analysis device, an image analysis system, and a control method for an image analysis system
WO2022157548A1 (en) 2021-01-24 2022-07-28 Forrest Michael David Inhibitors of atp synthase - cosmetic and therapeutic uses

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351829A (en) 1980-09-26 1982-09-28 Farmitalia Carlo Erba Spa Use of polypeptides as analgesic drugs
DE69321962T2 (de) 1992-08-21 1999-07-01 Biogen Inc Von tat abgeleitete transportpolypeptide
US5776685A (en) * 1993-07-19 1998-07-07 Joslin Diabetes Center Protein kinase C assay
US5935803A (en) 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US5783405A (en) 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US6165977A (en) 1996-10-18 2000-12-26 Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase C methods and compositions
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
US6218113B1 (en) * 1998-02-24 2001-04-17 Incyte Genomics, Inc. Human protein kinase C inhibitor
CA2336709A1 (en) 1998-07-06 2000-01-13 Robert O. Messing Use of inhibitors of protein kinase c epsilon to treat pain
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
AU5116099A (en) * 1998-07-21 2000-02-14 Sui Xiong Cai Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
CN1313895A (zh) * 1998-09-14 2001-09-19 泛太平洋制药公司 蜂毒蛋白的有用特性和编码这种蜂毒蛋白的基因
EP1115847A1 (en) * 1998-09-25 2001-07-18 Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
GB9905218D0 (en) * 1999-03-09 1999-04-28 Univ Glasgow Neurodegenerative disorder related gene
JP2003516760A (ja) * 1999-12-02 2003-05-20 ユニヴァーシティー オブ ダンディー プロテインキナーゼ調節
CN1300845A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人二酰基甘油蛋白激酶亚单位9和编码这种多肽的多核苷酸
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6496425B1 (en) * 2000-08-21 2002-12-17 Micron Technology, Inc Multiple bit line column redundancy
CA2434643C (en) * 2001-01-18 2013-10-29 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of.delta.pkc
WO2003089456A2 (en) * 2002-04-22 2003-10-30 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c

Similar Documents

Publication Publication Date Title
JP2012176978A5 (enExample)
JP2005523326A5 (enExample)
CA2482598A1 (en) Peptide inhibitors of protein kinase c
JP2012501973A5 (enExample)
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
IL262976A (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
FI3642340T3 (fi) Muunneltu l-asparaginaasi
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
TWI455721B (zh) 癌疫苗組合物
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
NZ602824A (en) Sparc binding peptides and uses thereof
JP2013533273A5 (enExample)
JP2008508859A5 (enExample)
JP2012115277A5 (enExample)
HRP20140616T1 (hr) Peptidni analog oksintomodulina
JP2013520405A5 (enExample)
JP2011250797A5 (enExample)
WO2012142320A3 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
JP2016502551A5 (enExample)
JPWO2019156137A5 (enExample)
JP2012529293A5 (enExample)
JP2015510393A5 (enExample)